Dr. Gupta on safety and sequencing of antibody-drug conjugates in urothelial cancer

Shilpa Gupta, MD, director of Genitourinary Oncology at Cleveland Clinic compares the safety profile of the antibody-drug conjugates (ADCs) sacituzumab govitecan (Trodelvy) and enfortumab vedotin (Padcev). Both ADCs are FDA-approved for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and a PD-1/PD-L1 inhibitor.